TRENDING :  Market Movers  |  Top 50   NBEV (-6.35%)    SPY (0.25%)    DGAZ (3.88%)    TSLA (0.48%)    UGAZ (-4.8%)    VXXB (2.02%)    VXX (1.76%)    UXIN (0.56%)    TWLO (-0.48%)    TLT (0.1%)    SQQQ (-0.15%)    CGC (1.94%)    AMD (-3.19%)    SPX (0.25%)    SM (0.86%)    PRQR (0.67%)    NFLX (-0.92%)    MNGA (-1.02%)    MBOT (8.93%)    INPX (2.15%)    HCLP (3.79%)

 ATHN - athenahealth

$133.52 (0.06%)

Next Earnings

1/31/2019

AMC



Analyst Rating

CompanyAnalyst NamePT ActionActionRatingTargetDate
Morgan StanleyGoldwasser RickyRaisesMaintainsEqual-Weight$135.0012/03/18
Wells FargoJamie StocktonAnnouncesDowngradesMarket Perform$135.0011/27/18

OPEN RECOMMENDATIONS

No recommendations found.


This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.

TRADERS TRACKING $ATHN

Service NameTrader% Success
Time is moneyChen Capital93.00 %Follow
baskervilleAlley Ramsey57.00 %Subscribe

TRENDING ARTICLES



Cerner (CERN) Teams Up With Nebraska-Based LRHC, Shares Up

12:00 AM
Maintaining its streak of collaborations Cerner Corporation CERN recently teamed up for a 10 year agreement with Nebraska based Lexington Regional Health Center LRHC Notably through the alliance Cerner s coveted Millennium platform will be transforming LRHC s electronic health

Integra LifeSciences Unveils Titan RSS-S, Widens Portfolio

01/11/19
Integra LifeSciences Holdings Corporation IART recently announced the completed commercial launch of the Integra Titan Reverse Shoulder System S RSS S 160 This latest offering includes a new glenoid baseplate design to expand the Integra Titan Reverse Shoulder System The launch is

Integra (IART) Rises 5% on Robust Preliminary Q4 Results

01/09/19
Shares of Integra LifeSciences Holdings Corporation IART gained 4 8 to close at 46 57 on Tuesday following the announcement of strong preliminary fourth quarter 2018 financial results The company is expected to release its final audited fourth quarter and full year financial report

ResMed Announces Complete Mobi Launch in US Markets for COPD

01/09/19
Following a successful initial launch ResMed Inc RMD announced a complete launch of its portable oxygen concentrator Mobi in the United States for chronic obstructive pulmonary disease COPD or other chronic diseases The company plans to launch Mobi in other countries in 2019 after

Boston Scientific Gains on Impressive Preliminary Q4 Results

01/09/19
Boston Scientific Corporation BSX recently announced preliminary revenue results for fourth quarter 2018 The company is slated to release its comprehensive financial results for the period on Feb 6 Boston Scientific projects an impressive fourth quarter performance and expects to meet

Hologic Stock Rides on Impressive Preliminary Q1 Result

01/08/19
Hologic Inc HOLX recently announced preliminary revenue results for first quarter fiscal 2019 The company is slated to release its comprehensive financial results for the period on Jan 30 Hologic projects an impressive performance in the fiscal first quarter and expects to surpass its

QIAGEN Scores on Strategic Alliances, Suffers Low HPV Sales

01/08/19
On Jan 7 we issued an updated research report on QIAGEN N V QGEN The company s business is expected to get a boost from its flourishing molecular diagnostic market international expansion extended test menu and growth driving strategic collaborations QIAGEN has outperformed

ResMed Closes Propeller Health Buyout, Boosts COPD Suite

01/08/19
ResMed Inc RMD recently closed the Propeller Health buyout for 225 million The deal was initiated in the last month Based in Wisconsin privately funded Propeller is a digital therapeutics company that offers connected health solutions for conditions like chronic obstructive

Neogen's Canadian Lab Buyout to Boost Genomics Business

01/07/19
Neogen Corporation 160 NEOG recently announced the acquisition of Delta Genomics Centre Based in Edmonton Delta is a leading animal genomics laboratory in Canada Meanwhile the financial terms of the agreement have been kept under wraps 160 Per management the buyout is expected to

Cardiovascular Systems Expands Portfolio Amid Stiff Rivalry

01/07/19
On Jan 4 we issued an updated research report on Cardiovascular Systems Inc 160 CSII The company has been pursuing product improvements and evaluating new technologies to strengthen and broaden its portfolio of powerful micro invasive tools However the company facing cut

AngioDynamics (ANGO) Q2 Earnings Beat on Gains From NanoKnife

01/07/19
AngioDynamics Inc ANGO reported second quarter fiscal 2019 adjusted earnings of 22 cents per share which edged past the Zacks Consensus Estimate by a penny The bottom line also surged 29 4 on a year over year basis Revenues totaled 91 5 million surpassing the Zacks Consensus Estimate

LabCorp Rides on Covance Business Amid Reimbursement Woes

01/07/19
On Jan 4 we issued an updated research report on LabCorp LH The stock carries a Zacks Rank 3 Hold This Burlington NC based healthcare diagnostics company providing comprehensive clinical laboratory services and end to end drug development support has been grappling with multiple

Here's Why You Should Hold on to Cerner (CERN) Stock for Now

01/04/19
A strong outlook for 2018 and a slew of developments are working in favor of Cerner Corporation CERN at present However an intensely competitive industry is concerning Over the past year shares of Cerner have plunged 26 5 compared with the industry s 17 7 decline The current level

Cerner (CERN) Collaborates With McKesson's CoverMyMeds

01/04/19
In a bid to enhance prescription price transparency Cerner Corporation CERN enters into collaboration with CoverMyMeds Per the deal Cerner will integrate patient specific information into the electronic health record EHR Notably CoverMyMeds is a wholly owned subsidiary of

Will Walgreens (WBA) Q1 Earnings Gain From Overall Strength?

12/18/18
Walgreens Boots Alliance Inc WBA is slated to release first quarter and fiscal 2019 results on Dec 11 before the market opens In the last reported quarter the company delivered a positive earnings surprise of 2 78 Walgreens Boots has outperformed the Zacks Consensus Estimate in the